ArticlePloS one2018
Population-based estimate of hepatitis C virus prevalence in Ontario, Canada.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening Program.Open forum infectious diseases · 2026Article
- Hepatitis C Screening: A Health Technology Assessment.Ontario health technology assessment series · 2026Article
- National hepatitis B and C estimates for 2021: Measuring Canada's progress towards eliminating viral hepatitis as a public health concern.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2025Article
- Epidemiology of Hepatitis C over 28 years of monitoring Canadian blood donors: Insight into a low-risk undiagnosed population.BMC public health · 2024Article
- Hepatitis C (HCV) prevalence in citizens of the Métis Nation of Ontario.BMC infectious diseases · 2024Article
- A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada.Scientific reports · 2023Article
- Barriers and Facilitators to Hepatitis C Virus (HCV) Treatment for Aboriginal and Torres Strait Islander Peoples in Rural South Australia: A Service Providers' Perspective.International journal of environmental research and public health · 2023Article
- National Hepatitis C estimates: Incidence, prevalence, undiagnosed proportion and treatment, Canada, 2019.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2022Article
- Birth cohort hepatitis C antibody prevalence in real-world screening settings in Ontario.Canadian liver journal · 2022Article
- Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada.Canadian liver journal · 2021Article
- Infection prevention and control lapse involving medical equipment reprocessing at a family medicine clinic in Ottawa, Ontario, 2018.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2020Article
- What Comes First: Treatment of Viral Hepatitis or Liver Cancer?Digestive diseases and sciences · 2019Review
- The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2018Article
- Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain.PloS one · 2018Article
- Contextualizing Canada's hepatitis C virus epidemic.Canadian liver journal · 2018Review
- The 7th Canadian Symposium on Hepatitis C Virus: "Toward Elimination of HCV: How to Get There".Canadian liver journal · 2018Article
- Descriptive epidemiology of hepatitis C in individuals referred for specialized HCV care in Newfoundland and Labrador, 1996-2014.Canadian liver journal · 2018Article
- Family medicine-directed hepatitis C care and barriers to treatment: a mixed-methods study.CMAJ openArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis C virus (HCV) is the most burdensome infectious illness in Canada. Current screening strategies miss a significant proportion of cases, leaving many undiagnosed. Elevated HCV prevalence in those born between 1945 and 1965 has prompted calls for birth-cohort screening in this group. However, Canada lacks population-level data to support this recommendation. We performed a serosurvey to obtain population-based HCV prevalence estimates in Ontario residents born between 1945-1974, to generate evidence for birth-cohort screening recommendations.
methodsWe tested anonymized residual sera in five-year age-sex bands from Ontario for anti-HCV antibody. We performed descriptive epidemiological analysis and used a logistic regression model to determine HCV risk-factors.
resultsOf 10,006 sera analyzed, 155 (1.55%, 95% confidence interval (CI) 1.32, 1.81) were positive for HCV antibody. Individuals born between 1950-1964 had a significantly higher combined prevalence of 1.92% (95% CI 1.56, 2.34) compared to 1.14% (95% CI 0.69, 1.77) (p = 0.04) for those born between 1970-1974. For males, comprising 107/155 (69.03%) of positive samples, the highest prevalence was 3.00% (95% CI 1.95, 4.39) for the 1960-1964 birth-cohort. For females, the highest prevalence was 1.56% (95% CI 0.83, 2.65) for those born between 1955-1959. Male sex was significantly associated with positive HCV serostatus.
interpretationHCV prevalence in Ontario is highest among those in this birth cohort, and higher than previous estimates. The prevalence estimates presented in our study provide important data to underpin birth-cohort screening recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.